A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2017
At a glance
- Drugs Everolimus (Primary) ; Letrozole (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 21 Mar 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
- 03 Jun 2016 Status changed from suspended to active, no longer recruiting.